Phase 3 N=110 SVT-15652 Otic Solution for the Treatment of Otomycosis.
Otomycosis
Primary: Therapeutic Cure (Clinical and Mycological Cure) — 59; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=570 Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Pneumococcal Disease · COVID-19 · SARS-CoV-2 Infection
Primary: Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination — 8.6; 9.7; 8.1; 0.0 Percentage of participants
Phase 3 N=216 Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
Lupus Nephritis
Primary: Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments. — 100; 80; 28; 21 Participants
Phase 3 N=26 Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
Attention Deficit Hyperactivity Disorder · ADHD
Primary: Comparison Following Treatment Between Drug and Placebo Using Evaluation by SKAMP Combined, Attention, and Deportment Scales — 1.46; 2.03 units on a scale — p=<0.01
Phase 3 N=151 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Neurodermatitis
Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…
Phase 3 N=148 Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
Meniere Disease
Primary: 28-Day Average DVD at Week 12 (Month 3) — 2.869; 3.577 DVD — p=0.312
Phase 3 N=110 Tdap Vaccine Safety for Plasma Donors
Tetanus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 71; 42; 0 participants
Phase 3 N=262 Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
Advanced Parkinson's Disease
Primary: Number of Participants With Treatment-emergent Adverse Events — 253; 219; 159; 152 Participants
Phase 3 N=17 Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
Heart Failure
Primary: Cmax — 8580; 2040 ng/mL
Phase 3 N=1,270 A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
Emergency Contraception
Primary: Proportion of Dosing Instances Among User Population Taken Within 120 Hours (5 Days) of Most Recent Episode of Unprotected Sex. — 704 Dosing instances 120 hrs of…
Phase 3 N=514 A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. — -1.6; -1.3 score on a scale…
Phase 3 N=4,446 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Anal Cancer · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years
Phase 3 N=1,191 Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 60.0; 65.5; 57.0; 59.1 Percentage of participants — p== 0.050
Phase 3 N=551 Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Severe Hypertriglyceridemia
Primary: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 — -56.00; -7.97 Percent of Change — p=<0.0001
Phase 3 N=121 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
Ureter Injury
Primary: Urine Jet Conspicuity Score — 4.1; 4.2; 2.5 score on a scale — p=<0.0001